NORMALIZED SECTIONS {'listoftablespagereftoc68776447h8': 'LIST OF TABLES PAGEREF _Toc68776447 \\h 8', '1protocolsummarypagereftoc68776448h9': '1. PROTOCOL SUMMARY PAGEREF _Toc68776448 \\h 9', '11synopsispagereftoc68776449h9': '1.1. Synopsis PAGEREF _Toc68776449 \\h 9', '12schemapagereftoc68776450h13': '1.2. Schema PAGEREF _Toc68776450 \\h 13', '13scheduleofactivitiespagereftoc68776451h14': '1.3. Schedule of Activities PAGEREF _Toc68776451 \\h 14', '2introductionpagereftoc68776452h16': '2. INTRODUCTION PAGEREF _Toc68776452 \\h 16', '21pneumococcaldiseasepagereftoc68776453h16': '2.1. Pneumococcal Disease PAGEREF _Toc68776453 \\h 16', '22vaccinestopreventpneumococcaldiseasepagereftoc68776454h16': '2.2. Vaccines to Prevent Pneumococcal Disease PAGEREF _Toc68776454 \\h 16', '221pneumococcalpolysaccharidevaccinespagereftoc68776455h16': '2.2.1. Pneumococcal Polysaccharide Vaccines PAGEREF _Toc68776455 \\h 16', '222pneumococcalpolysaccharideconjugatevaccinespagereftoc68776456h17': '2.2.2. Pneumococcal Polysaccharide Conjugate Vaccines PAGEREF _Toc68776456 \\h 17', '23developmentof20vpncpagereftoc68776457h18': '2.3. Development of 20vPnC PAGEREF _Toc68776457 \\h 18', '24indicationpagereftoc68776458h19': '2.4. Indication PAGEREF _Toc68776458 \\h 19', '25coronavirusdisease2019covid19pagereftoc68776459h19': '2.5. Coronavirus Disease 2019 (COVID19) PAGEREF _Toc68776459 \\h 19', '26studyrationalepagereftoc68776460h20': '2.6. Study Rationale PAGEREF _Toc68776460 \\h 20', '27backgroundpagereftoc68776461h20': '2.7. Background PAGEREF _Toc68776461 \\h 20', '271clinicaloverviewpagereftoc68776462h21': '2.7.1. Clinical Overview PAGEREF _Toc68776462 \\h 21', '28benefitriskassessmentpagereftoc68776463h21': '2.8. Benefit/Risk Assessment PAGEREF _Toc68776463 \\h 21', '281riskassessmentpagereftoc68776464h23': '2.8.1. Risk Assessment PAGEREF _Toc68776464 \\h 23', '282benefitassessmentpagereftoc68776465h25': '2.8.2. Benefit Assessment PAGEREF _Toc68776465 \\h 25', '283overallbenefitriskconclusionpagereftoc68776466h25': '2.8.3. Overall Benefit/Risk Conclusion PAGEREF _Toc68776466 \\h 25', '3objectivesendpointsandestimandspagereftoc68776467h25': '3. OBJECTIVES, ENDPOINTS, and estimands PAGEREF _Toc68776467 \\h 25', '4studydesignpagereftoc68776468h26': '4. STUDY DESIGN PAGEREF _Toc68776468 \\h 26', '41overalldesignpagereftoc68776469h26': '4.1. Overall Design PAGEREF _Toc68776469 \\h 26', '42scientificrationaleforstudydesignpagereftoc68776470h28': '4.2. Scientific Rationale for Study Design PAGEREF _Toc68776470 \\h 28', '421diversityofstudypopulationpagereftoc68776471h28': '4.2.1. Diversity of Study Population PAGEREF _Toc68776471 \\h 28', '422choiceofcontraceptionbarrierrequirementspagereftoc68776472h28': '4.2.2. Choice of Contraception/Barrier Requirements PAGEREF _Toc68776472 \\h 28', '43justificationfordosepagereftoc68776473h29': '4.3. Justification for Dose PAGEREF _Toc68776473 \\h 29', '44endofstudydefinitionpagereftoc68776474h29': '4.4. End of Study Definition PAGEREF _Toc68776474 \\h 29', '5studypopulationpagereftoc68776475h29': '5. STUDY POPULATION PAGEREF _Toc68776475 \\h 29', '51inclusioncriteriapagereftoc68776476h29': '5.1. Inclusion Criteria PAGEREF _Toc68776476 \\h 29', '52exclusioncriteriapagereftoc68776477h31': '5.2. Exclusion Criteria PAGEREF _Toc68776477 \\h 31', '53lifestyleconsiderationspagereftoc68776478h32': '5.3. Lifestyle Considerations PAGEREF _Toc68776478 \\h 32', '531contraceptionpagereftoc68776479h32': '5.3.1. Contraception PAGEREF _Toc68776479 \\h 32', '54screenfailurespagereftoc68776480h33': '5.4. Screen Failures PAGEREF _Toc68776480 \\h 33', '55criteriafortemporarilydelayingenrollmentrandomizationadministrationofstudyinterventionpagereftoc68776481h33': '5.5. Criteria for Temporarily Delaying Enrollment/Randomization/Administration of Study Intervention PAGEREF _Toc68776481 \\h 33', '6studyinterventionsandconcomitanttherapypagereftoc68776482h33': '6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY PAGEREF _Toc68776482 \\h 33', '61studyinterventionsadministeredpagereftoc68776483h33': '6.1. Study Intervention(s) Administered PAGEREF _Toc68776483 \\h 33', '611administrationpagereftoc68776484h34': '6.1.1. Administration PAGEREF _Toc68776484 \\h 34', '612medicaldevicespagereftoc68776485h35': '6.1.2. Medical Devices PAGEREF _Toc68776485 \\h 35', '62preparationhandlingstorageandaccountabilitypagereftoc68776486h35': '6.2. Preparation, Handling, Storage, and Accountability PAGEREF _Toc68776486 \\h 35', '621preparationanddispensingpagereftoc68776487h36': '6.2.1. Preparation and Dispensing PAGEREF _Toc68776487 \\h 36', '63measurestominimizebiasrandomizationandblindingpagereftoc68776488h37': '6.3. Measures to Minimize Bias: Randomization and Blinding PAGEREF _Toc68776488 \\h 37', '631allocationtostudyinterventionpagereftoc68776489h37': '6.3.1. Allocation to Study Intervention PAGEREF _Toc68776489 \\h 37', '632blindingofsitepersonnelpagereftoc68776490h37': '6.3.2. Blinding of Site Personnel PAGEREF _Toc68776490 \\h 37', '633blindingofthesponsorpagereftoc68776491h38': '6.3.3. Blinding of the Sponsor PAGEREF _Toc68776491 \\h 38', '634breakingtheblindpagereftoc68776492h38': '6.3.4. Breaking the Blind PAGEREF _Toc68776492 \\h 38', '64studyinterventioncompliancepagereftoc68776493h38': '6.4. Study Intervention Compliance PAGEREF _Toc68776493 \\h 38', '65dosemodificationpagereftoc68776494h39': '6.5. Dose Modification PAGEREF _Toc68776494 \\h 39', '66continuedaccesstostudyinterventionaftertheendofthestudypagereftoc68776495h39': '6.6. Continued Access to Study Intervention After the End of the Study PAGEREF _Toc68776495 \\h 39', '67treatmentofoverdosepagereftoc68776496h39': '6.7. Treatment of Overdose PAGEREF _Toc68776496 \\h 39', '68concomitanttherapypagereftoc68776497h39': '6.8. Concomitant Therapy PAGEREF _Toc68776497 \\h 39', '681prohibitedduringthestudypagereftoc68776498h39': '6.8.1. Prohibited During the Study PAGEREF _Toc68776498 \\h 39', '682permittedduringthestudypagereftoc68776499h40': '6.8.2. Permitted During the Study PAGEREF _Toc68776499 \\h 40', '7discontinuationofstudyinterventionandparticipantdiscontinuationwithdrawalpagereftoc68776500h40': '7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL PAGEREF _Toc68776500 \\h 40', '71discontinuationofstudyinterventionpagereftoc68776501h40': '7.1. Discontinuation of Study Intervention PAGEREF _Toc68776501 \\h 40', '72participantdiscontinuationwithdrawalfromthestudypagereftoc68776502h40': '7.2. Participant Discontinuation/Withdrawal From the Study PAGEREF _Toc68776502 \\h 40', '721withdrawalofconsentpagereftoc68776503h41': '7.2.1. Withdrawal of Consent PAGEREF _Toc68776503 \\h 41', '73losttofollowuppagereftoc68776504h42': '7.3. Lost to FollowUp PAGEREF _Toc68776504 \\h 42', '8studyassessmentsandprocedurespagereftoc68776505h42': '8. STUDY ASSESSMENTS AND PROCEDURES PAGEREF _Toc68776505 \\h 42', '81efficacyandorimmunogenicityassessmentspagereftoc68776506h43': '8.1. Efficacy and/or Immunogenicity Assessments PAGEREF _Toc68776506 \\h 43', '811immunogenicityassessmentspagereftoc68776507h43': '8.1.1. Immunogenicity Assessments PAGEREF _Toc68776507 \\h 43', '812biologicalsamplespagereftoc68776508h44': '8.1.2. Biological Samples PAGEREF _Toc68776508 \\h 44', '82safetyassessmentspagereftoc68776509h44': '8.2. Safety Assessments PAGEREF _Toc68776509 \\h 44', '821participantelectronicdiarypagereftoc68776510h44': '8.2.1. Participant Electronic Diary PAGEREF _Toc68776510 \\h 44', '822gradingscaleforpromptedeventspagereftoc68776511h45': '8.2.2. Grading Scale for Prompted Events PAGEREF _Toc68776511 \\h 45', '8221localreactionspagereftoc68776512h45': '8.2.2.1. Local Reactions PAGEREF _Toc68776512 \\h 45', '8222systemiceventssystemicsymptomsandfeverpagereftoc68776513h46': '8.2.2.2. Systemic Events – Systemic Symptoms and Fever PAGEREF _Toc68776513 \\h 46', '8223useofantipyreticpainmedicationpagereftoc68776514h48': '8.2.2.3. Use of Antipyretic/Pain Medication PAGEREF _Toc68776514 \\h 48', '823clinicalsafetylaboratoryassessmentspagereftoc68776515h48': '8.2.3. Clinical Safety Laboratory Assessments PAGEREF _Toc68776515 \\h 48', '83adverseeventsseriousadverseeventsandothersafetyreportingpagereftoc68776516h48': '8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting PAGEREF _Toc68776516 \\h 48', '831timeperiodandfrequencyforcollectingaeandsaeinformationpagereftoc68776517h49': '8.3.1. Time Period and Frequency for Collecting AE and SAE Information PAGEREF _Toc68776517 \\h 49', '8311reportingsaestopfizersafetypagereftoc68776518h49': '8.3.1.1. Reporting SAEs to Pfizer Safety PAGEREF _Toc68776518 \\h 49', '8312recordingnonseriousaesandsaesonthecrfpagereftoc68776519h50': '8.3.1.2. Recording Nonserious AEs and SAEs on the CRF PAGEREF _Toc68776519 \\h 50', '832methodofdetectingaesandsaespagereftoc68776520h50': '8.3.2. Method of Detecting AEs and SAEs PAGEREF _Toc68776520 \\h 50', '833followupofaesandsaespagereftoc68776521h50': '8.3.3. FollowUp of AEs and SAEs PAGEREF _Toc68776521 \\h 50', '834regulatoryreportingrequirementsforsaespagereftoc68776522h50': '8.3.4. Regulatory Reporting Requirements for SAEs PAGEREF _Toc68776522 \\h 50', '835environmentalexposureexposureduringpregnancyorbreastfeedingandoccupationalexposurepagereftoc68776523h51': '8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and Occupational Exposure PAGEREF _Toc68776523 \\h 51', '8351exposureduringpregnancypagereftoc68776524h51': '8.3.5.1. Exposure During Pregnancy PAGEREF _Toc68776524 \\h 51', '8352exposureduringbreastfeedingpagereftoc68776525h53': '8.3.5.2. Exposure During Breastfeeding PAGEREF _Toc68776525 \\h 53', '8353occupationalexposurepagereftoc68776526h53': '8.3.5.3. Occupational Exposure PAGEREF _Toc68776526 \\h 53', '836cardiovascularanddeatheventspagereftoc68776527h53': '8.3.6. Cardiovascular and Death Events PAGEREF _Toc68776527 \\h 53', '837diseaserelatedeventsandordiseaserelatedoutcomesnotqualifyingasaesorsaespagereftoc68776528h53': '8.3.7. DiseaseRelated Events and/or DiseaseRelated Outcomes Not Qualifying as AEs or SAEs PAGEREF _Toc68776528 \\h 53', '838adverseeventsofspecialinterestpagereftoc68776529h54': '8.3.8. Adverse Events of Special Interest PAGEREF _Toc68776529 \\h 54', '8381lackofefficacypagereftoc68776530h54': '8.3.8.1. Lack of Efficacy PAGEREF _Toc68776530 \\h 54', '839medicaldevicedeficienciespagereftoc68776531h54': '8.3.9. Medical Device Deficiencies PAGEREF _Toc68776531 \\h 54', '8391timeperiodfordetectingmedicaldevicedeficienciespagereftoc68776532h54': '8.3.9.1. Time Period for Detecting Medical Device Deficiencies PAGEREF _Toc68776532 \\h 54', '8392followupofmedicaldevicedeficienciespagereftoc68776533h54': '8.3.9.2. FollowUp of Medical Device Deficiencies PAGEREF _Toc68776533 \\h 54', '8393promptreportingofdevicedeficienciestothesponsorpagereftoc68776534h55': '8.3.9.3. Prompt Reporting of Device Deficiencies to the Sponsor PAGEREF _Toc68776534 \\h 55', '8394regulatoryreportingrequirementsfordevicedeficienciespagereftoc68776535h55': '8.3.9.4. Regulatory Reporting Requirements for Device Deficiencies PAGEREF _Toc68776535 \\h 55', '8310medicationerrorspagereftoc68776536h55': '8.3.10. Medication Errors PAGEREF _Toc68776536 \\h 55', '84pharmacokineticspagereftoc68776537h56': '8.4. Pharmacokinetics PAGEREF _Toc68776537 \\h 56', '85geneticspagereftoc68776538h56': '8.5. Genetics PAGEREF _Toc68776538 \\h 56', '86biomarkerspagereftoc68776539h57': '8.6. Biomarkers PAGEREF _Toc68776539 \\h 57', '87immunogenicityassessmentspagereftoc68776540h57': '8.7. Immunogenicity Assessments PAGEREF _Toc68776540 \\h 57', '88healtheconomicspagereftoc68776541h57': '8.8. Health Economics PAGEREF _Toc68776541 \\h 57', '89studyprocedurespagereftoc68776542h57': '8.9. Study Procedures PAGEREF _Toc68776542 \\h 57', '891visit1day1pagereftoc68776543h57': '8.9.1. Visit 1 (Day 1) PAGEREF _Toc68776543 \\h 57', '892visit221to35daysaftervisit1pagereftoc68776544h60': '8.9.2. Visit 2 (21 to 35 Days After Visit 1) PAGEREF _Toc68776544 \\h 60', '893visit36months168to196daysaftervisit1pagereftoc68776545h61': '8.9.3. Visit 3 (6 Months [168 to 196 Days] After Visit 1) PAGEREF _Toc68776545 \\h 61', '894unscheduledvisitspagereftoc68776546h61': '8.9.4. Unscheduled Visits PAGEREF _Toc68776546 \\h 61', '9statisticalconsiderationspagereftoc68776547h62': '9. STATISTICAL CONSIDERATIONS PAGEREF _Toc68776547 \\h 62', '91statisticalhypothesespagereftoc68776548h62': '9.1. Statistical Hypotheses PAGEREF _Toc68776548 \\h 62', '911estimandspagereftoc68776549h62': '9.1.1. Estimands PAGEREF _Toc68776549 \\h 62', '92analysissetspagereftoc68776550h63': '9.2. Analysis Sets PAGEREF _Toc68776550 \\h 63', '93statisticalanalysespagereftoc68776551h64': '9.3. Statistical Analyses PAGEREF _Toc68776551 \\h 64', '931generalconsiderationspagereftoc68776552h64': '9.3.1. General Considerations PAGEREF _Toc68776552 \\h 64', '9311analysisforbinarydatapagereftoc68776553h64': '9.3.1.1. Analysis for Binary Data PAGEREF _Toc68776553 \\h 64', '9312analysisforcontinuousdatapagereftoc68776554h64': '9.3.1.2. Analysis for Continuous Data PAGEREF _Toc68776554 \\h 64', '932primaryendpointsestimandsanalysispagereftoc68776555h65': '9.3.2. Primary Endpoint(s)/Estimand(s) Analysis PAGEREF _Toc68776555 \\h 65', '933secondaryendpointsestimandsanalysispagereftoc68776556h65': '9.3.3. Secondary Endpoint(s)/Estimand(s) Analysis PAGEREF _Toc68776556 \\h 65', '934tertiaryexploratoryendpointspagereftoc68776557h66': '9.3.4. Tertiary/Exploratory Endpoint(s) PAGEREF _Toc68776557 \\h 66', '94interimanalysespagereftoc68776558h66': '9.4. Interim Analyses PAGEREF _Toc68776558 \\h 66', '941analysistimingpagereftoc68776559h66': '9.4.1. Analysis Timing PAGEREF _Toc68776559 \\h 66', '95samplesizedeterminationpagereftoc68776560h67': '9.5. Sample Size Determination PAGEREF _Toc68776560 \\h 67', '10supportingdocumentationandoperationalconsiderationspagereftoc68776561h68': '10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS PAGEREF _Toc68776561 \\h 68', '101appendix1regulatoryethicalandstudyoversightconsiderationspagereftoc68776562h68': '10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations PAGEREF _Toc68776562 \\h 68', '1011regulatoryandethicalconsiderationspagereftoc68776563h68': '10.1.1. Regulatory and Ethical Considerations PAGEREF _Toc68776563 \\h 68', '10111reportingofsafetyissuesandseriousbreachesoftheprotocolorichgcppagereftoc68776564h68': '10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP PAGEREF _Toc68776564 \\h 68', '1012financialdisclosurepagereftoc68776565h69': '10.1.2. Financial Disclosure PAGEREF _Toc68776565 \\h 69', '1013informedconsentprocesspagereftoc68776566h69': '10.1.3. Informed Consent Process PAGEREF _Toc68776566 \\h 69', '1014dataprotectionpagereftoc68776567h70': '10.1.4. Data Protection PAGEREF _Toc68776567 \\h 70', '1015committeesstructurepagereftoc68776568h70': '10.1.5. Committees Structure PAGEREF _Toc68776568 \\h 70', '10151datamonitoringcommitteepagereftoc68776569h70': '10.1.5.1. Data Monitoring Committee PAGEREF _Toc68776569 \\h 70', '1016disseminationofclinicalstudydatapagereftoc68776570h70': '10.1.6. Dissemination of Clinical Study Data PAGEREF _Toc68776570 \\h 70', '1017dataqualityassurancepagereftoc68776571h72': '10.1.7. Data Quality Assurance PAGEREF _Toc68776571 \\h 72', '1018sourcedocumentspagereftoc68776572h73': '10.1.8. Source Documents PAGEREF _Toc68776572 \\h 73', '1019studyandsitestartandclosurepagereftoc68776573h73': '10.1.9. Study and Site Start and Closure PAGEREF _Toc68776573 \\h 73', '10110publicationpolicypagereftoc68776574h74': '10.1.10. Publication Policy PAGEREF _Toc68776574 \\h 74', '10111sponsorsqualifiedmedicalpersonnelpagereftoc68776575h75': '10.1.11. Sponsor’s Qualified Medical Personnel PAGEREF _Toc68776575 \\h 75', '102appendix2clinicallaboratorytestspagereftoc68776576h76': '10.2. Appendix 2: Clinical Laboratory Tests PAGEREF _Toc68776576 \\h 76', '103appendix3adverseeventsdefinitionsandproceduresforrecordingevaluatingfollowupandreportingpagereftoc68776577h77': '10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, FollowUp, and Reporting PAGEREF _Toc68776577 \\h 77', '1031definitionofaepagereftoc68776578h77': '10.3.1. Definition of AE PAGEREF _Toc68776578 \\h 77', '1032definitionofansaepagereftoc68776579h78': '10.3.2. Definition of an SAE PAGEREF _Toc68776579 \\h 78', '1033recordingreportingandfollowupofaesandorsaesduringtheactivecollectionperiodpagereftoc68776580h80': '10.3.3. Recording/Reporting and FollowUp of AEs and/or SAEs During the Active Collection Period PAGEREF _Toc68776580 \\h 80', '1034reportingofsaespagereftoc68776581h83': '10.3.4. Reporting of SAEs PAGEREF _Toc68776581 \\h 83', '104appendix4contraceptiveandbarrierguidancepagereftoc68776582h85': '10.4. Appendix 4: Contraceptive and Barrier Guidance PAGEREF _Toc68776582 \\h 85', '1041maleparticipantreproductiveinclusioncriteriapagereftoc68776583h85': '10.4.1. Male Participant Reproductive Inclusion Criteria PAGEREF _Toc68776583 \\h 85', '1042femaleparticipantreproductiveinclusioncriteriapagereftoc68776584h85': '10.4.2. Female Participant Reproductive Inclusion Criteria PAGEREF _Toc68776584 \\h 85', '1043womanofchildbearingpotentialpagereftoc68776585h85': '10.4.3. Woman of Childbearing Potential PAGEREF _Toc68776585 \\h 85', '1044contraceptionmethodspagereftoc68776586h86': '10.4.4. Contraception Methods PAGEREF _Toc68776586 \\h 86', '105appendix5liversafetysuggestedactionsandfollowupassessmentspagereftoc68776587h88': '10.5. Appendix 5: Liver Safety: Suggested Actions and FollowUp Assessments PAGEREF _Toc68776587 \\h 88', '106appendix6aesadessaessadesusadesanddevicedeficienciesdefinitionsandproceduresforrecordingevaluatingfollowupandreportinginmedicaldevicestudiespagereftoc68776588h90': '10.6. Appendix 6: AEs, ADEs, SAEs, SADEs, USADEs, and Device Deficiencies: Definitions and Procedures for Recording, Evaluating, FollowUp, and Reporting in Medical Device Studies PAGEREF _Toc68776588 \\h 90', '1061definitionofaeandadepagereftoc68776589h90': '10.6.1. Definition of AE and ADE PAGEREF _Toc68776589 \\h 90', '1062definitionofsaesadeandusadepagereftoc68776590h90': '10.6.2. Definition of SAE, SADE, and USADE PAGEREF _Toc68776590 \\h 90', '1063definitionofdevicedeficiencypagereftoc68776591h91': '10.6.3. Definition of Device Deficiency PAGEREF _Toc68776591 \\h 91', '1064recordingreportingandfollowupofmedicaldevicedeficienciespagereftoc68776592h91': '10.6.4. Recording/Reporting and Follow-Up of Medical Device Deficiencies PAGEREF _Toc68776592 \\h 91', '1065reportingofsaespagereftoc68776593h93': '10.6.5. Reporting of SAEs PAGEREF _Toc68776593 \\h 93', '1066reportingofsadespagereftoc68776594h93': '10.6.6. Reporting of SADEs PAGEREF _Toc68776594 \\h 93', '107appendix7alternativemeasuresduringpublicemergenciespagereftoc68776595h94': '10.7. Appendix 7:  Alternative Measures During Public Emergencies PAGEREF _Toc68776595 \\h 94', '1071telehealthvisitspagereftoc68776596h94': '10.7.1. Telehealth Visits PAGEREF _Toc68776596 \\h 94', '1072homehealthvisitspagereftoc68776597h94': '10.7.2. Home Health Visits PAGEREF _Toc68776597 \\h 94', '1073adverseeventsandseriousadverseeventspagereftoc68776598h95': '10.7.3. Adverse Events and Serious Adverse Events PAGEREF _Toc68776598 \\h 95', '108appendix8abbreviationspagereftoc68776599h96': '10.8. Appendix 8: Abbreviations PAGEREF _Toc68776599 \\h 96', '109appendix9criteriaforallowinginclusionofparticipantswithchronicstablehivorhbvinfectionorcuredhcvinfectionpagereftoc68776600h99': '10.9. Appendix 9: Criteria for Allowing Inclusion of Participants With Chronic Stable HIV or HBV Infection or Cured HCV Infection PAGEREF _Toc68776600 \\h 99', '11referencespagereftoc68776601h100': '11. References PAGEREF _Toc68776601 \\h 100', 'table1gradingscalesforlocalreactionspagereftoc68776602h46': 'Table\xa01.Grading Scales for Local Reactions PAGEREF _Toc68776602 \\h 46', 'table2gradingscalesforsystemiceventspagereftoc68776603h47': 'Table 2.Grading Scales for Systemic Events PAGEREF _Toc68776603 \\h 47', 'table3rangesforfeverpagereftoc68776604h48': 'Table 3.Ranges for Fever PAGEREF _Toc68776604 \\h 48', 'table4probabilityofdetectingatleast1aepagereftoc68776605h67': 'Table 4.Probability of Detecting at Least 1 AE PAGEREF _Toc68776605 \\h 67', 'appendix8': 'Appendix 8', 'appendix4': 'Appendix 4', 'appendix1': 'Appendix 1', 'soa': 'SoA', 'appendix3': 'Appendix\xa03', 'appendix6': 'Appendix\xa06', 'refref21414371rhmergeformat834': 'REF _Ref21414371 \\r \\h  \\* MERGEFORMAT 8.3.4'}NORMALIZED TEXT NORMALIZED TEXT NORMALIZED TEXT aphase3randomizeddoubleblindtrialtodescribethesafetyandimmunogenicityof20valentpneumococcalconjugatevaccinewhencoadministeredwithaboosterdoseofbnt162b2inadults65yearsofageandolderNORMALIZED TEXT NORMALIZED TEXT NORMALIZED TEXT documenthistoryNORMALIZED TEXT NORMALIZED TEXT NORMALIZED TEXT tableofcontentsNORMALIZED TEXT listoftables8NORMALIZED TEXT 1protocolsummary9NORMALIZED TEXT 11synopsis9NORMALIZED TEXT 12schema13NORMALIZED TEXT 13scheduleofactivities14NORMALIZED TEXT 2introduction16NORMALIZED TEXT 21pneumococcaldisease16NORMALIZED TEXT 22vaccinestopreventpneumococcaldisease16NORMALIZED TEXT 221pneumococcalpolysaccharidevaccines16NORMALIZED TEXT 222pneumococcalpolysaccharideconjugatevaccines17NORMALIZED TEXT 23developmentof20vpnc18NORMALIZED TEXT 24indication19NORMALIZED TEXT 25coronavirusdisease2019covid1919NORMALIZED TEXT 26studyrationale20NORMALIZED TEXT 27background2
has context menu
